Founded in 2005, Guangzhou LBP Medicine Science & Technology Co.,Ltd. was listed on the SSE STAR Market of Shanghai Stock Exchange on August 20, 2020 , which is the first listed company in the field of pathological diagnosis in China.
Since its establishment, LBP has been constructing a diversified technology platform, developed a number of core technologies such as sedimentation liquid-based cytology technology, reverse dot blot hybridization PCR preparation technology, real-time PCR preparation technology, FISH probe labeling technology, IHC pathological diagnosis screening and quality control technology and related supporting instrument manufacturing technology, and is one of the most complete and diverse manufacturers in the field of pathological diagnosis in China, which can meet the needs of medical institutions at different levels. LBP has obtained the certificate of National High-Tech Enterprise, and 9 of its core products have won the title of "Guangdong High-Tech Product", as well as many honors such as Guangdong Innovative Enterprise (Pilot) in 2018, Guangdong Pathology Diagnosis Engineering Technology Research Center, etc. The products have passed CE European Authentication, British Standards Institution and the Ministry of Health, Labour, and Welfare of Japan Quality Certification. In the past years, LBP has participated in a number of major national, provincial, and municipal projects under the "863 Program", and has obtained 61 authorized patents, including 17 invention patents, 26 software copyrights, and has more than 500 registered/recorded products, which is increasing continuously. With theindependently-developed reagents and instruments, perfect marketing network and high-quality service system, LBP's products have covered nearly 1,800 medical institutions nationwide.
LBP always takes "Create value for society and customers and realize the goal of employees and enterprises" as its enterprise vision. In the future, LBP will engaged in developing and producing in-vitro diagnostic products of good quality. To fulfill this goal, LBP has newly-built an industrial park of nearly 30,000㎡ in Science City, Guangzhou.
| Full name | Guangzhou LBP Medicine Science & Technology Co., Ltd. |
|---|---|
| Abbreviations | LBP Medicine |
| Code | 688393 |
| Founded | July 6, 2005 |
| Listing | August 20,2020 |
| Domicile | Guangzhou |
| Website | http://www.gzlbp.com |
| zqswb@gzlbp.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 1.09 | 1.06 | 0.88 |
| R&D expenditure as a % of operating revenue | 7.39% | 6.15% | 5.09% |
| Operating Revenue | 375.43 | 355.16 | 306.30 |
| Net Income | 83.62 | 72.80 | 62.42 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 375.43 | 355.16 | 306.30 |
| Operating Costs | 75.96 | 57.94 | 52.17 |
| Operating Income | 100.20 | 88.80 | 74.36 |
| Pretax Income | 99.85 | 87.25 | 74.47 |
| Income Tax | 16.23 | 14.45 | 12.05 |
| Net Income | 83.62 | 72.80 | 62.42 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,062.92 | 365.97 | 328.75 |
| Non-current Assets-Total | 229.33 | 171.99 | 147.81 |
| Total Assets | 1,292.25 | 537.96 | 476.56 |
| Liabilities | |||
| Current Liabilities-Total | 87.41 | 57.76 | 54.59 |
| Non-current Liabilities-Total | 37.26 | 35.57 | 32.65 |
| Total Liabilities | 124.67 | 93.33 | 87.24 |
| Stockholder's Equity | |||
| Share Capital | 844.82 | 204.87 | 204.87 |
| Retained Profits | 323.15 | 238.41 | 181.92 |
| Minority interests | -0.39 | 1.35 | 2.53 |
| Total Owners' Equity | 1,167.58 | 444.63 | 389.32 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 91.43 | 89.74 | 65.35 |
| Net Cash Flows-Investing | -183.31 | -59.78 | -46.98 |
| Net Cash Flows-Financing | 639.33 | -19.22 | -17.13 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 蔡向挺 | 19.82 | 21.23% |
| 广州市凯多投资咨询中心（有限合伙） | 12.95 | 13.88% |
| 诸暨高特佳睿安投资合伙企业（有限合伙） | 6.14 | 6.58% |
| 余江县乾靖企业管理中心（有限合伙） | 6.06 | 6.49% |
| 广州市达安基因科技有限公司 | 3.49 | 3.73% |
| 道远资本管理（北京）有限公司－厦门运资股权投资合伙企业（有限合伙） | 3.40 | 3.64% |
| 重庆高特佳睿安股权投资基金合伙企业（有限合伙） | 2.61 | 2.80% |
| 广东中大一号投资有限合伙企业（有限合伙） | 2.33 | 2.50% |
| 曲水唯实创业投资合伙企业（有限合伙） | 2.15 | 2.31% |
| 杭州高特佳睿海投资合伙企业（有限合伙） | 1.85 | 1.99% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.